Immediate results and late clinical outcomes after new CrossFlex coronary stent implantation

Seung Jung Park, Seong Wook Park, Cheol Whan Lee, Myeong Ki Hong, Jae Joong Kim, Hoon Ki Park, Mun K. Hong, Gary S. Mintz, Martin B. Leon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This study evaluates the safety and efficacy of the new CrossFlex stent in the treatment of native coronary artery disease. The CrossFlex stent is a flexible, balloon-expandable new device with an excellent flexibility, radial strength, conformability, and radio-opacity. Little data are available concerning the clinical and angiographic outcomes of this device. The CrossFlex stent was implanted in 209 consecutive patients with 226 lesions. Follow-up angiography was performed at 6 months, and clinical evaluation was undertaken at regular intervals after stent implantation. Procedural success was achieved in all lesions without in-hospital complications. Angiographic follow-up data were available in 153 of the 187 eligible lesions (follow-up rate, 82%), and the overall angiographic restenosis rate was 16.3%. Minimal lumen diameter immediately after stent placement was the only predictor of angiographic restenosis. Clinical follow-up was obtained in all patients at 10.5 ± 5.2 months. There were 4 deaths (1 cardiac in origin, the others noncardiac in origin), and 1 nonfatal myocardial infarction (nonstented artery) during follow-up. Target lesion revascularization was required in 15 patients (7%), and the overall event-free survival rate (death, myocardial infarction, and repeat revascularization) was 87% at the end of the follow- up period. The CrossFlex stent is a safe and effective device with a high procedural success rate, and a favorable late clinical outcome for treatment of native coronary artery disease. Further randomized trials are needed to compare the CrossFlex stent with standard slotted-tube stents.

Original languageEnglish
Pages (from-to)502-506
Number of pages5
JournalAmerican Journal of Cardiology
Volume83
Issue number4
DOIs
Publication statusPublished - 1999 Feb 15

Fingerprint

Stents
Equipment and Supplies
Coronary Artery Disease
Myocardial Infarction
Radio
Disease-Free Survival
Angiography
Survival Rate
Arteries
Safety

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Park, Seung Jung ; Park, Seong Wook ; Lee, Cheol Whan ; Hong, Myeong Ki ; Kim, Jae Joong ; Park, Hoon Ki ; Hong, Mun K. ; Mintz, Gary S. ; Leon, Martin B. / Immediate results and late clinical outcomes after new CrossFlex coronary stent implantation. In: American Journal of Cardiology. 1999 ; Vol. 83, No. 4. pp. 502-506.
@article{ceadbb56a4894bb98de2189550ad0676,
title = "Immediate results and late clinical outcomes after new CrossFlex coronary stent implantation",
abstract = "This study evaluates the safety and efficacy of the new CrossFlex stent in the treatment of native coronary artery disease. The CrossFlex stent is a flexible, balloon-expandable new device with an excellent flexibility, radial strength, conformability, and radio-opacity. Little data are available concerning the clinical and angiographic outcomes of this device. The CrossFlex stent was implanted in 209 consecutive patients with 226 lesions. Follow-up angiography was performed at 6 months, and clinical evaluation was undertaken at regular intervals after stent implantation. Procedural success was achieved in all lesions without in-hospital complications. Angiographic follow-up data were available in 153 of the 187 eligible lesions (follow-up rate, 82{\%}), and the overall angiographic restenosis rate was 16.3{\%}. Minimal lumen diameter immediately after stent placement was the only predictor of angiographic restenosis. Clinical follow-up was obtained in all patients at 10.5 ± 5.2 months. There were 4 deaths (1 cardiac in origin, the others noncardiac in origin), and 1 nonfatal myocardial infarction (nonstented artery) during follow-up. Target lesion revascularization was required in 15 patients (7{\%}), and the overall event-free survival rate (death, myocardial infarction, and repeat revascularization) was 87{\%} at the end of the follow- up period. The CrossFlex stent is a safe and effective device with a high procedural success rate, and a favorable late clinical outcome for treatment of native coronary artery disease. Further randomized trials are needed to compare the CrossFlex stent with standard slotted-tube stents.",
author = "Park, {Seung Jung} and Park, {Seong Wook} and Lee, {Cheol Whan} and Hong, {Myeong Ki} and Kim, {Jae Joong} and Park, {Hoon Ki} and Hong, {Mun K.} and Mintz, {Gary S.} and Leon, {Martin B.}",
year = "1999",
month = "2",
day = "15",
doi = "10.1016/S0002-9149(98)00903-5",
language = "English",
volume = "83",
pages = "502--506",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "4",

}

Park, SJ, Park, SW, Lee, CW, Hong, MK, Kim, JJ, Park, HK, Hong, MK, Mintz, GS & Leon, MB 1999, 'Immediate results and late clinical outcomes after new CrossFlex coronary stent implantation', American Journal of Cardiology, vol. 83, no. 4, pp. 502-506. https://doi.org/10.1016/S0002-9149(98)00903-5

Immediate results and late clinical outcomes after new CrossFlex coronary stent implantation. / Park, Seung Jung; Park, Seong Wook; Lee, Cheol Whan; Hong, Myeong Ki; Kim, Jae Joong; Park, Hoon Ki; Hong, Mun K.; Mintz, Gary S.; Leon, Martin B.

In: American Journal of Cardiology, Vol. 83, No. 4, 15.02.1999, p. 502-506.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immediate results and late clinical outcomes after new CrossFlex coronary stent implantation

AU - Park, Seung Jung

AU - Park, Seong Wook

AU - Lee, Cheol Whan

AU - Hong, Myeong Ki

AU - Kim, Jae Joong

AU - Park, Hoon Ki

AU - Hong, Mun K.

AU - Mintz, Gary S.

AU - Leon, Martin B.

PY - 1999/2/15

Y1 - 1999/2/15

N2 - This study evaluates the safety and efficacy of the new CrossFlex stent in the treatment of native coronary artery disease. The CrossFlex stent is a flexible, balloon-expandable new device with an excellent flexibility, radial strength, conformability, and radio-opacity. Little data are available concerning the clinical and angiographic outcomes of this device. The CrossFlex stent was implanted in 209 consecutive patients with 226 lesions. Follow-up angiography was performed at 6 months, and clinical evaluation was undertaken at regular intervals after stent implantation. Procedural success was achieved in all lesions without in-hospital complications. Angiographic follow-up data were available in 153 of the 187 eligible lesions (follow-up rate, 82%), and the overall angiographic restenosis rate was 16.3%. Minimal lumen diameter immediately after stent placement was the only predictor of angiographic restenosis. Clinical follow-up was obtained in all patients at 10.5 ± 5.2 months. There were 4 deaths (1 cardiac in origin, the others noncardiac in origin), and 1 nonfatal myocardial infarction (nonstented artery) during follow-up. Target lesion revascularization was required in 15 patients (7%), and the overall event-free survival rate (death, myocardial infarction, and repeat revascularization) was 87% at the end of the follow- up period. The CrossFlex stent is a safe and effective device with a high procedural success rate, and a favorable late clinical outcome for treatment of native coronary artery disease. Further randomized trials are needed to compare the CrossFlex stent with standard slotted-tube stents.

AB - This study evaluates the safety and efficacy of the new CrossFlex stent in the treatment of native coronary artery disease. The CrossFlex stent is a flexible, balloon-expandable new device with an excellent flexibility, radial strength, conformability, and radio-opacity. Little data are available concerning the clinical and angiographic outcomes of this device. The CrossFlex stent was implanted in 209 consecutive patients with 226 lesions. Follow-up angiography was performed at 6 months, and clinical evaluation was undertaken at regular intervals after stent implantation. Procedural success was achieved in all lesions without in-hospital complications. Angiographic follow-up data were available in 153 of the 187 eligible lesions (follow-up rate, 82%), and the overall angiographic restenosis rate was 16.3%. Minimal lumen diameter immediately after stent placement was the only predictor of angiographic restenosis. Clinical follow-up was obtained in all patients at 10.5 ± 5.2 months. There were 4 deaths (1 cardiac in origin, the others noncardiac in origin), and 1 nonfatal myocardial infarction (nonstented artery) during follow-up. Target lesion revascularization was required in 15 patients (7%), and the overall event-free survival rate (death, myocardial infarction, and repeat revascularization) was 87% at the end of the follow- up period. The CrossFlex stent is a safe and effective device with a high procedural success rate, and a favorable late clinical outcome for treatment of native coronary artery disease. Further randomized trials are needed to compare the CrossFlex stent with standard slotted-tube stents.

UR - http://www.scopus.com/inward/record.url?scp=0033557543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033557543&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(98)00903-5

DO - 10.1016/S0002-9149(98)00903-5

M3 - Article

C2 - 10073851

AN - SCOPUS:0033557543

VL - 83

SP - 502

EP - 506

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 4

ER -